NCCN guidelines adapt to meet lung cancer treatment needs

Hatim Husain, MD, discusses how the National Comprehensive Cancer Network (NCCN) treatment guidelines adapt to meet the treatment needs of lung cancer patients.

Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, explains how the National Comprehensive Cancer Network (NCCN) treatment guidelines are adapting to meet the treatment needs of lung cancer patients , including providing guidance for molecularly guided therapies as new indications are approved.


How have NCCN guidelines evolved as new targeted therapies for lung cancer have been approved?

The NCCN guidelines have included new guidance for new agents where appropriate. This list is growing, with recent additions including KRAS, atypical EGFR variants with the insertion of exon 20, as well as additions in MEET and also considerations for developing agents and type of pending results, including HER2.

The NCCN has really been instrumental in terms of including approved guidelines for a number of different new indications for molecularly guided therapies, as well as emerging ones. And I think that’s an important consideration. Some of the emerging molecular-guided therapies that have been listed in the NCCN guidelines include MET inhibitors for copy number gain or expression enhancement, as well as for HER2-Specifically for HER2 mutations in protein expression or copy number gain that may be important in breast cancer.

NCCN guidelines have evolved to include agents approved for molecularly guided approaches, as well as emerging therapies, and provide an understanding of the applicability of these agents, particularly in circumstances where there is high MET amplification as well as HER2 changes.

About Michael Bill

Check Also

Putin doesn’t think invading Ukraine a ‘mistake’: Scholz | Russo-Ukrainian War

German Chancellor says there is no indication Putin has changed his stance on Ukraine as …